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Allogeneic  hematopoietic  cell  transplantation 
(allo-HCT) is a potentially curative treatment 
for many patients with high-risk hematological 
malignancies (Rabinowe et al., 1993; van Besien 
et al., 1998; Pavletic et al., 2000; Alyea et al., 
2001; Bishop et al., 2003; Dreger et al., 2003; 
Maris et al., 2004; Peggs et al., 2005; Sorror et al., 
2005). The success of allo-HCT is largely based 
on  immunological  graft-versus-tumor  effects 
mediated by allogeneic T lymphocytes present 
in the graft (Collin et al., 2007). Unfortunately, 
this beneficial effect is counterbalanced by the 
occurrence  of  graft-versus-host  reactions  di-
rected against normal host tissues resulting in 
graft-versus-host disease (GVHD), a potentially 
life-threatening complication which limits the 
success of allo-HCT. GVHD may manifest as 
inflammation of the host tissue including, but 
not limited to, the skin, liver, and gut. De-
pending on the degree of genetic disparity be-
tween allogeneic donor and recipient, GVHD 
may occur in up to 75% and may lead to death 
in up to 20% of transplant recipients (Mielcarek 
et al., 2003). Therefore, a major objective in 
allo-HCT is the prevention of GVHD.
Studies in the last decade have led to the 
concept that tissue injuries induced by the 
transplantation regimen activate host APCs, 
which in turn control the priming of donor 
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Acute graft-versus-host disease (GVHD) results from the attack of host tissues by donor 
allogeneic T cells and is the most serious limitation of allogeneic hematopoietic cell trans-
plantation (allo-HCT). Host antigen-presenting cells are thought to control the priming of 
alloreactive T cells and the induction of acute GVHD after allo-HCT. However, whereas the 
role of host DC in GVHD has been established, the contribution of host macrophages to 
GVHD has not been clearly addressed. We show that, in contrast to DC, reducing of the host 
macrophage pool in recipient mice increased donor T cell expansion and aggravated GVHD 
mortality after allo-HCT. We also show that host macrophages that persist after allo-HCT 
engulf donor allogeneic T cells and inhibit their proliferation. Conversely, administration of 
the cytokine CSF-1 before transplant expanded the host macrophage pool, reduced donor  
T cell expansion, and improved GVHD morbidity and mortality after allo-HCT. This study 
establishes the unexpected key role of host macrophages in inhibiting GVHD and identifies 
CSF-1 as a potential prophylactic therapy to limit acute GVHD after allo-HCT in the clinic.
© 2011 Hashimoto et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). After   
six  months  it  is  available  under  a  Creative  Commons  License  (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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Anti–CSF-1 receptor (R) blocking mAb eliminates host 
macrophages that persist in lethally irradiated mice
The CSF-1R is expressed on all monocytes and tissue macro-
phages and is thought to play a key role in the homeostasis of 
these cells (Chitu and Stanley, 2006). CSF-1R has two ligands 
that include the cytokine CSF-1 and a newly identified cyto-
kine called IL-34 (Lin et al., 2008). IL-34/ mice are not yet 
available, but csf-1op/op mice (Cecchini et al., 1994) that carry 
a natural null mutation in the gene encoding the CSF-1 pro-
tein (Felix et al., 1990; Wiktor-Jedrzejczak et al., 1990;   
Yoshida et al., 1990) and csf-1r/ mice lack tissue macro-
phages (Cecchini et al., 1994; Dai et al., 2002; Fig. S2 A). 
Circulating  monocytes,  including  the  Gr-1low  and  Gr-1high 
subsets, are also reduced in csf-1r/ and csf-1op/op mice, al-
though the Gr-1low subset is more strongly affected in these 
mice (Fig. S2 B and not depicted). Although we found that 
CSF-1R is expressed on a subset of DCs that express high lev-
els of the CD11b integrin in lymphoid and nonlymphoid tis-
sues (Ginhoux et al., 2009), csf-1r/ mice only lack CD11b+ 
DC in nonlymphoid tissues whereas lymphoid organ DC re-
mained intact in these mice (Ginhoux et al., 2006, 2009).
Based on these findings, we thought to use a blocking anti–
CSF-1R  mAb  to  determine  whether  CSF-1R  blockade  in 
mice could be used to eliminate lymphoid tissue macrophages 
without affecting lymphoid tissue DC. We found that systemic 
administration of anti–CSF-1R mAb in C57BL/6 mice strongly 
reduced red pulp spleen macrophages as well as LN medullary 
and subcapsular sinus macrophages (Fig. 2, A and D). Circulating 
monocytes were also significantly reduced upon systemic ad-
ministration of anti–CSF-1R mAb treatment (Fig. 2, C and F). 
Strikingly, the Gr-1low monocytes subset was much more af-
fected than the Gr-1high monocyte subset, suggesting that CSF-1 
signaling controls the differentiation of Gr-1high into Gr-1low 
monocytes in vivo (Fig. 2, C and F). In contrast, spleen and LN 
DCs, T cells, B cells, NK cells, and neutrophils were not af-
fected by the mAb treatment (Fig. 2, B and E; and Fig. S3).
T cells to host tissue antigens and the induction of GVH re-
actions. This concept is based on a series of studies pio-
neered in experimental mouse models of GVHD showing 
that BM chimeric mice in which host hematopoietic cells 
are unable to prime donor T cells are protected from GVHD 
after allo-HCT (Shlomchik et al., 1999), whereas alloanti-
gen expression on host target epithelium is not essential for 
alloreactive T cell attack of the skin, liver, and intestine of 
recipient animals (Teshima et al., 2002). Previous studies, 
including ours, have shown that DCs are potent initiators 
of GVHD (Duffner et al., 2004; Merad et al., 2004; Koyama 
et al., 2009). Consistently, the use of liposomal clodronate 
(Lip-Clod) to deplete both host macrophages and DC lim-
ited GVHD and improved survival after transplant (Zhang 
et al., 2002b).
Similar to other adaptive immune responses (Miller et al., 
2002; Mempel et al., 2004), GVHD is initiated upon priming 
of alloreactive T cells by host APC in secondary lymphoid or-
gans during the first days after allo-HCT (Panoskaltsis-Mortari   
et al., 2004; Beilhack et al., 2005; Na et al., 2010). Therefore, 
host APCs that survive the conditioning regimen and remain 
in lymphoid organs during the first days that follow the injec-
tion of alloreactive T cells are uniquely capable of shaping do-
nor T cell immune responses to host antigens (Zhang et al., 
2002a). We have recently shown that recipient macrophages 
resist the conditioning regimen and persist in patients for many 
weeks after allo-HCT (Haniffa et al., 2009), providing ample 
opportunity to modulate donor T cell immunity. However, 
although the role of DC in GVHD has been established, the 
exact role of host macrophages in the induction of alloimmune 
responses has not been clearly addressed.
In this study, we examined the contribution of host   
macrophages to acute GVHD using an experimental mouse 
model of allo-HCT. Unexpectedly, we found that in contrast 
to host DC, host macrophages that resist the conditioning 
regimen play a key role in modulating the induction of allo-
reactive T cell immune responses and limit the severity of 
GVH reactions after allo-HCT.
RESULTS
Macrophages persist in lymphoid tissues after  
lethal irradiation
Remaining host APCs that resist the conditioning regimen 
play a key role in shaping donor T cell immunity (Collin et al., 
2007). To examine whether host lymphoid tissue macro-
phages  influence  donor  T  cell  immunity  after  allo-HCT, 
C57BL/6 mice (H-2b) were exposed to total body irradiation 
(TBI; 13 Gy). Recipient mice were then sacrificed at differ-
ent time points after TBI to examine the rate of macrophage 
decline in the spleen and LN. The number of spleen red pulp 
macrophages and LN medullary and subcapsular sinus macro-
phages was unchanged at 48 h and significant numbers of 
macrophages persisted at 96 h after TBI (Fig. 1 A). In con-
trast, DC and B cells were strongly reduced by 48 h after TBI 
(Fig. 1, B and C). Neutrophils, T cells, and NK cells were 
also quickly eliminated after TBI (Fig. S1, A–C).
Figure 1.  Macrophages persist in lymphoid tissues for several days 
after TBI. C57BL/6 mice were sacrificed 48 h (gray bars, n = 6) and 96 h 
(black bars, n = 6) after TBI (13 Gy). Nonirradiated C57BL/6 mice were 
used as controls (white bars, n = 4–8). The number of remaining host 
macrophages (A), DCs (B), and B cells (C) in the spleen (top) and mesen-
teric LN (bottom) are shown as mean ± SEM. Pooled data from two inde-
pendent experiments are shown. M, macrophage.JEM VOL. 208, May 9, 2011 
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anti–CSF-1R mAb injections before transplant strongly re-
duced the spleen and LN macrophage pool (Fig. 2, G, H, and 
K), whereas spleen and LN DCs, as well as neutrophils, re-
mained unaffected by the treatment (Fig. 2, I and J).
Anti–CSF-1R  mAb–induced  macrophage  depletion 
could potentially be mediated via different mechanisms that 
include complement-dependent cytotoxicity, which requires 
the cleavage of the C3 complement component (Ehlenberger 
To examine whether anti–CSF-1R mAb could also be 
used to eliminate host macrophages that remain in lymphoid 
tissues after allo-HCT, recipient mice received three consec-
utive injections of anti–CSF-1R mAb or isotype Ab control 
starting 5 d before lethal irradiation and allo-HCT. Mice 
were sacrificed 2 d after transplant to measure the effect of 
the anti–CSF-1R mAb on the remaining host macrophage 
pool. Consistent with the results obtained in naive mice, 
Figure 2.  Pretransplant anti–CSF-1R mAb (CSF-1R) administration depletes remaining host lymphoid tissue macrophages. (A–F) Mice were 
injected with CSF-1R (black bar, n = 11) or rat IgG (white bar, n = 9) for 3 d and were sacrificed 5 d after the last injection. The numbers of spleen and LN 
macrophages (A and D), spleen and LN DCs (B and E), and circulating neutrophils and monocytes (C and F) are shown. In the LN panel shown in A, dot 
plots show the percentage of LN macrophages among CD11b+ gated cells. Other dot plots depicted in A and B show percentage of DCs or macrophages 
among total spleen or LN cells. Data from three independent experiments are pooled and shown as mean ± SEM. *, P < 0.05; **, P < 0.001. (G–K) C57BL/6 
mice were injected i.p. with CSF-1R (black bar, n = 10) or isotype IgG (white bar, n = 7–11) from days 5 to 3, were lethally irradiated and reconsti-
tuted with allogeneic BM and splenocytes on day 0, and were then sacrificed 2 d later. The relative (G) and absolute (H) numbers of remaining host spleen 
and LN macrophages and the absolute numbers of spleen and LN DCs (I) and spleen neutrophils (J) are shown. Data from three independent experiments 
are combined and shown as mean ± SEM. *, P < 0.05; **, P < 0.001. (K) Images show frozen sections of spleens stained for CD169+ marginal zone metal-
lophilic macrophages. Bars, 100 µm.1072 CSF-1 modulates graft-versus-host disease | Hashimoto et al.
5  to  3, 
lethally irradi-
ated on day 0,   
and  injected 
with BM cells   
together with 2.5 or 10 × 106 splenocytes isolated from 
MHC-mismatch allogeneic BALB/c (H-2d) mice or syngeneic 
C57BL/6 mice. Severe GVHD occurred in recipient mice 
injected with 10 × 106 splenocytes, leading to the death of 
all animals by day 65 after transplant, whereas 40% of the re-
cipient mice injected with 2.5 × 106 splenocytes survived 
>90 d after transplant. Unexpectedly, anti–CSF-1R adminis-
tration exacerbated GVHD morbidity (Fig. 3 B) and mortal-
ity after allo-HCT, leading to the death of all recipient mice 
including those injected with low-dose allogeneic T cells by 
day 30 after transplant (Fig. 3, A, C, and D). In contrast, 
anti–CSF-1R mAb did not affect the outcome of lethally ir-
radiated C57BL/6 mice reconstituted with syngeneic hema-
topoietic cells (Fig. 3, A and B), indicating that the adverse 
effect of anti–CSF-1R mAb occurs only in the context of al-
logeneic transplantation. In addition, anti–CSF-1R mAb 
treatment did not compromise donor hematopoietic cell en-
graftment after transplant, as lethally irradiated mice that re-
ceived allogeneic hematopoietic cells were fully chimeric by 
and Nussenzweig, 1977), antibody-dependent cell-mediated 
cytotoxicity (ADCC), which requires the engagement of an 
intact FcR chain on recipient macrophages, or the blockade 
of  c-fms  signaling.  The  AFS98  anti–CSF-1R  mAb  clone 
used in this study depleted host macrophages as efficiently in 
mice deficient in C3 (Fig. S4 A) or FcR (Fig. S4 B) as in 
wild-type mice, suggesting that macrophage depletion oc-
curred independently of complement-dependent cytotoxic-
ity or ADCC and was likely mainly a result of the inhibition 
of CSF-1 signaling. Consistently, we found that GW2580, a 
small molecule which inhibits c-fms signaling, had a similar 
effect to AFS98 on macrophages in vivo (Fig. S4 C). Based 
on these findings, we concluded that AFS98-mediated macro-
phage depletion is dependent on c-fms blockade.
Anti–CSF-1R mAb administration before allo-HCT 
exacerbates GVHD
The ability of anti–CSF-1R mAb to eliminate lymphoid tis-
sue macrophages but not lymphoid tissue DC provides a tool 
to specifically assess the role of host macrophages in allo-
HCT outcome. To examine whether elimination of con-
ditioning-resistant host macrophages could affect GVHD 
outcome after allo-HCT, recipient C57BL/6 mice were 
treated with anti–CSF-1R mAb or rat IgG control from days 
Figure 3.  Anti–CSF-1R (CSF-1R) mAb treat-
ment exacerbates GVHD without impairing donor 
hematopoietic cell engraftment. (A and B) C57BL/6 
mice (n = 5–6/group) were injected i.p. with CSF-1R 
(solid lines, diamond) or control rat IgG (dashed lines, 
triangle) on days 5 to 3, lethally irradiated (13 Gy), 
and injected i.v. on day 0 with 2.5 (open symbols) or 10 
(closed symbols) × 106 splenocytes plus 5 × 106 BM 
cells isolated from BALB/c mice. As controls, syngeneic 
C57BL/6 CD45.2+ mice (open circle, n = 3/group) were 
treated with anti–CSF-1R (solid lines) or rat IgG 
(dashed lines) on days 5 to 3, lethally irradiated 
(13 Gy), and i.v. injected on day 0 with 2.5 × 106 sple-
nocytes plus 5 × 106 BM cells isolated from C57BL/6 
CD45.1+ congenic mice. Graphs show survival curves 
after transplant (A) and clinical GVHD scores reported 
as mean ± SEM (B). *, P < 0.005; **, P < 0.05 versus 
allogeneic rat IgG-treated groups. (C) H&E staining of 
liver (i, ii, and iii) and colon (iv, v, and vi) sections har-
vested 20 d after transplant from mice treated with 
CSF-1R before syngeneic HCT (i and iv) or mice 
treated with rat IgG (ii and v) or CSF-1R (iii and vi) 
before allo-HCT. Arrowheads show inflammatory infil-
trates accumulating in liver tissue sections. Bars, 100 µm.  
(D) Pathological GVHD scores from syngeneic recipi-
ents (white bar, n = 6), allogeneic recipients treated 
with rat IgG (gray bar, n = 6), and allogeneic recipients 
treated with CSF-1R (black bar, n = 6) are shown as 
mean ± SEM. Scores were analyzed on day 20  
after transplant and calculated as the sum of the 
scores of liver, small intestine, and colon. *, P < 0.005.  
(E–G) White blood cells in peripheral blood were 
counted and analyzed by flow cytometry 11 d after 
allo-HCT. Percent donor chimerism among myeloid and 
lymphoid subsets (E), absolute numbers of total blood 
leukocytes (F), and circulating CD11b+ myeloid cells  
(G) are shown. Horizontal bars indicate mean. Data 
from one of two similar experiments were shown.JEM VOL. 208, May 9, 2011 
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GVHD aggravation by CSF-1R mAb is independent of its 
effect on macrophages. To better assess the role of host macro-
phages in GVHD, we used Lip-Clod which has a deleting   
effect that is limited to DC and macrophages in vivo (Van 
Rooijen  and  Sanders,  1994).  To  specifically  examine  the 
contribution  of  host  macrophages  in  the  pathogenesis  of 
GVHD and to circumvent the depletion of DC, we took   
advantage  of  the  faster  turnover  of  lymphoid  tissue  DC   
compared  with  macrophages.  Consistent  with  a  previous 
study (Okamoto et al., 2008), we found that 10 d after Lip-
Clod injection, spleen DCs, as well as circulating monocytes, 
day 11 (Fig. 3 E). The white blood cell count in peripheral 
blood and the number of myeloid cells were also equivalent 
in anti–CSF-1R mAb-treated and control recipients (Fig. 3, 
F and G). Aggravation of GVHD by the anti–CSF-1R mAb 
was not strain dependent, as similar results were obtained 
when BALB/c recipient mice were reconstituted with allo-
geneic hematopoietic progenitors and alloreactive T cells iso-
lated  from  C57BL/6  mice  (unpublished  data).  Altogether 
these results suggest that CSF-1R–expressing cells play a key 
role in limiting GVHD after allo-HCT.
Anti–CSF-1R mAb administration dramatically increases 
donor T cell expansion and cytokine release after allo-HCT
Alloreactive T cells are responsible for the induction of acute 
graft-versus-host reactions (Collin et al., 2007). In this study, 
we measured the effect of anti–CSF-1R mAb on the fate of 
donor allogeneic T cells in recipient animals. The numbers of 
donor CD4+ and CD8+ T cells were dramatically enhanced 
in the spleen, LN, and liver of mice treated with anti–CSF-1R 
mAb compared with control mice (Fig. 4, A–C). IFN- and 
TNF, two cytokines shown to play a role in the efferent and 
afferent phases of acute GVHD (Jenq and van den Brink, 
2010), were elevated in the sera of mice treated with anti–
CSF-1R mAb before allo-HCT compared with the control 
animals (Fig. 4, D and E). Th2 cytokines, such as IL-13 and 
IL-4, were either slightly decreased or below detection levels 
in both groups (Fig. 4 F and not depicted). Importantly, ad-
ministration of anti–CSF-1R mAb did not affect the differ-
entiation of donor Foxp3+ T cells after allo-HCT, suggesting 
that donor T cell expansion in these mice was not a result   
of the modulation of donor T regulatory cell differentiation   
in vivo (Fig. S5, A and B).
Remaining host CSF-1R–positive cells modulate GVHD  
after allo-HCT
Anti–CSF-1R mAb persists in the circulation for many days 
after transplant (unpublished data). Therefore, aggravation of 
GVHD by anti–CSF-1R mAb could potentially be mediated 
by donor CSF-1R–expressing cells. To address this hypothe-
sis, recipient C57BL/6 mice treated with anti–CSF-1R mAb 
were lethally irradiated and injected with highly purified do-
nor T cells without additional donor BM cells and spleno-
cytes to avoid injecting donor CSF-1R–expressing cells. 
Similar to the results in the previous section, anti–CSF-1R 
mAb enhanced the expansion of adoptively transferred allo-
geneic BALB/c T cells but not congenic C57BL/6 CD45.1+ 
T cells injected into lethally irradiated C57BL/6 CD45.2+ 
mice (Fig. 4, G–L). Because naive and activated T cells lack 
CSF-1R expression (Fig. S5 C), these results suggest that 
anti–CSF-1R mAb modulates GVHD through its effect on 
host and not donor CSF-1R–expressing cells.
Low-dose Lip-Clod treatment exacerbates GVHD  
when administered 10 d before allo-HCT
Because CSF-1R expression is not limited to myeloid cells 
(Dai et al., 2002; Menke et al., 2009), it is possible that 
Figure 4.  Pretransplant anti–CSF-1R mAb (CSF1R) injection 
enhances donor T cell expansion through its effect on host CSF-
1R–expressing cells. (A–F) C57BL/6 mice were treated with CSF-1R 
(black bars, n = 10) or control rat IgG (gray bars, n = 13) on days 5 to 3, 
lethally irradiated, and i.v. injected on day 0 with 5 × 106 splenocytes  
plus 5 × 106 BM cells isolated from BALB/c mice. Absolute numbers of 
spleen, LN, and liver donor T cells identified as H2Kd+TCR+CD4+ or 
H2Kd+TCR+CD8+ cells (A–C) and serum cytokine levels (pg/ml; D–F) mea-
sured on day 6 after transplant are shown as mean ± SEM. Data were 
pooled from three independent experiments. (G–L) C57BL/6 CD45.2+ mice 
were injected i.p. with CSF-1R mAb on days 5 to 3, lethally irradi-
ated, and injected on day 0 with 2 × 106 purified T cells isolated from 
congenic C57BL/6 CD45.1+ mice (G–I) or allogeneic BALB/c mice  
(J–L). Absolute numbers of donor T cells in the spleen, mesenteric LN, and 
liver analyzed on day 5 after transfer are shown as mean ± SEM. Data 
were pooled from two independent experiments. *, P < 0.05; **, P < 0.005.1074 CSF-1 modulates graft-versus-host disease | Hashimoto et al.
proliferation or that 
the blocking mAb 
used in this culture 
does not fully block 
TGF- activity (Fig. S7, F and G). However, addition to 
inducible nitric oxide synthase (iNOS) inhibitor (L-NMMA), 
Arginase 1 inhibitor (nor-NOHA), IDO inhibitor (1-MT), 
and  IL-10  blocking  mAb  failed  to  reverse  the  suppressive 
function of macrophages in these cultures (Fig. S7, F and G). 
We also found that macrophages isolated from IFN- recep-
tor knockout and iNOS knockout mice suppressed donor 
T cells as efficiently as macrophages isolated from wild-type 
mice (Fig. S7 F).
Remaining host macrophages engulf donor allogeneic T cell 
in a CD47-dependent manner
Importantly,  using  the  same  in  vitro  culture  system  de-
scribed in the previous section, we found that macrophages 
reduced the number of allogeneic T cells, but not alloge-
neic B cells or syngenic T cells, long before the initiation of 
T cell proliferation (Fig. 6, A–G). Consistently, we found 
that host macrophages engulfed alloreactive T cells between 
2 and 18 h of in vitro culture (Fig. 6, H–J) and, thus, much 
more efficiently than host DC (Fig. 6, I and J). To examine 
whether host macrophages can also engulf donor T cells   
in vivo, we traced the fate of alloreactive T cells during the 
18 h after their injection in lethally irradiated recipient mice. 
Alloreactive T cells accumulated near the spleen marginal 
zone shortly after adoptive transfer and gradually shifted to-
ward the T cell area (Fig. 7, A and B). A large number of 
donor T cells were trapped in the red pulp in close contact 
with host macrophages at early time points after their trans-
fer (Fig. 7, A and B). Consistent with results obtained in 
cultures,  CFSE-labeled  donor  T  cells  were  engulfed  by 
splenic macrophages during the first day of transplant (Fig. 7, 
C–E) and before the initiation of donor T cell proliferation 
in vivo (not depicted). Strikingly, 18 h after allo-HCT, the 
number  of  donor  T  cells  accumulating  in  the  recipient 
spleen and mesenteric LN were significantly higher in mice 
treated with anti–CSF-1R mAb compared with the control 
recovered to normal levels (Fig. 5, A and B; and not de-
picted), whereas macrophages remained significantly reduced 
(Fig. 5, A and B). Similarly, nonlymphoid tissue DCs, in-
cluding cutaneous, lung, liver, and intestinal DCs, were pres-
ent in similar numbers in mice treated with Lip-Clod or 
Liposomal PBS (Fig. S6), enabling us to assess the contribu-
tion of macrophages and CSF-1R+ DC in modulating GVHD 
outcome after allo-HCT. Similar to the results observed   
using anti–CSF-1R mAb, Lip-Clod administered 10 d before 
transplant significantly increased GVHD mortality (Fig. 5 C) 
and morbidity (Fig. 5 D), confirming the key role of host 
macrophages in modulating GVHD after allo-HCT.
Host macrophages reduce alloreactive T cell  
proliferation in vitro
The results in the previous section demonstrate that in con-
trast to host DC, the depletion of host macrophages before 
allo-HCT aggravates GVHD clinical outcome, enhances do-
nor T cell expansion, and increases the release of Th1 cyto-
kines.  Next,  we  explored  the  mechanisms  by  which  host 
macrophages could potentially control donor T cell expansion 
induced by host DC after allo-HCT. Therefore, purified allo-
geneic BALB/c T cells and host C57BL/6 spleen DC were 
co-cultured in the presence or absence of host C57BL/6 macro-
phages purified from allogeneic recipient mice 2 d after 
transplant to mimic host APC–donor T cell interactions that   
occur in the recipient lymphoid tissues after allo-HCT. We 
found that host macrophages, but not host B cells, inhibited 
the proliferation of alloreactive T cells cultured in the pres-
ence of host DC in a dose-dependent manner (Fig. S7, A and 
C–E) and were more efficient at inhibiting allogeneic CD4+ 
T cell proliferation than CD8+ T cells. The use of a transwell 
co-culture system to prevent macrophages/T cell–cell contact 
partly reversed the suppression of T cell proliferation, suggest-
ing that soluble factors secreted by host macrophages inhibited 
T cells proliferation. Importantly, we found that anti–TGF- 
blocking  mAb  significantly  reduced  macrophage  ability  to 
suppress allogeneic proliferation without fully restoring T cell 
proliferation levels, suggesting that molecules other than TGF- 
control macrophages ability to suppress allogeneic T cell 
Figure 5.  Lip-Clod administered 10 d 
before allo-HCT exacerbates acute GVHD 
through the specific depletion of host 
macrophages. (A) Dot plots show the relative 
number of DC and macrophages among total 
splenocytes in C57BL/6 mice that were un-
treated or injected with 100 µl Lip-Clod and 
analyzed 2 or 10 d after injection. (B) The ab-
solute numbers of splenic macrophages and 
DC in Lip-Clod–treated mice (black bars, n = 5) 
and control mice (white bar, n = 5) are shown 
as mean ± SEM. Data from one of two similar 
experiments were shown. (C and D) C57BL/6 
mice were injected with 100 µl Lip-Clod (solid 
lines, diamonds) or PBS (dashed lines, trian-
gles) 10 d before allo-HCT. Graphs show sur-
vival curves (C) and clinical GVHD scores 
presented as mean ± SEM (D). *, P < 0.05. Data 
are pooled from two independent experiments.JEM VOL. 208, May 9, 2011 
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into  lethally  irradiated  allogeneic  recipients.  As  expected, 
CD47/ donor T cells were quickly eliminated from the 
host and a higher number of wild-type T cells survived, re-
sulting in a higher CD47+/+/CD47/ T cell ratio in recip-
ients (Fig. 7, G and I–K). The skewed ratio was observed as 
early as 18 h after transfer and before the initiation of T cell 
proliferation (Fig. 7 I). Depletion of macrophages before 
injection of CD47+/+ and CD47/ mixed T cells dramati-
cally prolonged the survival of CD47/ T cells and, to a 
lesser extent, CD47+/+ T cells (Fig. 7 K), correcting the 
skewed CD47+/+/CD47/ T cell ratio observed in recipi-
ent  mice  (Fig.  7,  G  and  I–K).  These  data  establish  that 
CD47 expression on donor T cells partly control macro-
phage ability to capture donor T cells after allo-HCT.
groups, whereas mAb treatment did not affect the numbers 
of donor B cell in the spleen (Fig. 7 F). Altogether, these 
results suggest that host macrophages limit the expansion of 
donor T cells partly through their ability to engulf donor 
allogeneic T cells. Because high CD47 expression protects 
cells from being captured by macrophages, we compared 
CD47 expression levels on naive T and B lymphocytes iso-
lated from spleen. We found that CD47 was expressed at 
lower levels on donor T cells compared with B cells (Fig. S8 A) 
but  was  up-regulated  on  proliferating  T  cells  stimulated 
with anti-CD3 mAb or allogeneic DC (Fig. S8, B and C; 
and not depicted). To examine whether CD47 plays a role 
in donor T cell homeostasis after allo-HCT, we coinjected 
106  T  cells  isolated  from  CD47+/+  and  CD47/  mice 
Figure 6.  Macrophages reduce the survival of allogeneic T cells before the initiation of T cell proliferation (A–F) C57BL/6 T cells (A and C), BALB/c  
T cells (B, D, and E), or BALB/c B cells (F) were co-cultured with C57BL/6 DC in the presence or absence of splenic (A, B, and F) or peritoneal (C and E) macro-
phages from C57BL/6 mice. In D, DC and macrophages were purified from BALB/c mice. Graphs show the survival index of remaining live T cells or B cells 
after 44 h of culture in the presence of macrophages. The survival index was calculated as the ratio of remaining live lymphocytes in each well to the mean 
of numbers of live lymphocytes in the wells without macrophages. Horizontal bars indicate mean. (G) BALB/c T cells were labeled with 5 µM CFSE before co-
culture with C57BL/6 DC in the presence or absence of C57BL/6 macrophages. CFSE dilution within TCR-–positive cells was analyzed after 48 h of culture. 
(H) Images show macrophages isolated after 18 h of in vitro co-culture (as described in G) contained CFSE+ material. Bars, 10 µm. (I and J) DCs and macro-
phages purified from C57BL/6 mice were cultured with or without PKH26-labeled BALB/c T cells. Phagocytosis of PKH26-labeled T cells by DC and macro-
phages were evaluated after 2 and 6 h of co-culture. (I) Dot plot shows the gating strategy for DC and macrophages. Doublets and dead cells were excluded 
from the analysis. Histograms show the presence of PKH26+ material in gated DC (top) and macrophages (bottom) cultured with (red lines) or without (blue 
shaded area) PKH26-labeled T cells. (J) The percentage of PKH26-positive cells among DCs (white bar) and macrophages (black bar) after 2 and 6 h of co-
culture are shown as mean ± SEM. B6, C57BL/6. *, P < 0.05. These results were representative of three independent experiments.1076 CSF-1 modulates graft-versus-host disease | Hashimoto et al.
Figure 7.  Host macrophages reduce the donor T cell pool partly though their ability to clear donor allogeneic T cells after allo-HCT. (A and B) Le-
thally irradiated C57BL/6 mice were injected with 6 × 106 CFSE-labeled BALB/c T cells. Sequential lengthwise frozen sections of whole spleens were made at the 
indicated time points after transfer. The section with maximal area was chosen and stained with anti-F4/80 (blue) and anti-CD3 (red) mAb. (A) Representative 
images at each time points are shown. The far right panel indicates that the F4/80-positive area and CD3-positive area are defined as red pulp and T cell zone, 
respectively and the unstained area is defined as marginal zone or B cell follicle. Bars, 500 µm. (B) Images of the whole sections were captured using an automatic 
motorized stage. CFSE+ T cells in each area were counted separately. The percentage of CFSE-labeled T cells in T cell zone (red), red pulp (blue), and marginal zone 
or B cell follicle (green) are shown as mean ± SEM. (C and D) Lethally irradiated C57BL/6 mice were injected with 3 × 106 CFSE-labeled BALB/c T cells and sacrificed 
1–2 h after transfer. Dot plots (C) show the gating strategy for recipient red pulp macrophages. The percentages of host macrophages that phagocytosed CFSE+ 
cells (D) upon adoptive transfer of CFSE+ T cells (filled circle) or noninjected controls (open circle) are shown. Data from one out of two separate experiments are 
shown. (E) Representative images of F4/80+ macrophages that engulfed CFSE-labeled T cells at 18 h after the transfer are shown. Bars, 10 µm. (F) B6 mice were 
treated with CSF-1R (filled circles) or rat IgG (open circles) from days 5 to 3 and lethally irradiated and injected with 5 × 106 CFSE-labeled splenocytes and  
5 × 106 CFSE-labeled BM cells on day 0. The absolute numbers of donor cells that accumulate in the recipient spleen 18 h after transfer are shown. Pooled data 
from three independent experiments were combined. Horizontal bars indicate mean. (G–K) BALB/c mice were treated with CSF-1R or rat IgG from days 5 to 3.  
On day 0, the recipient mice were lethally irradiated and injected with 3 × 106 wild-type T cell–depleted BM cells together with 106 CD45.2+ B6 CD47 knockout 
(KO) T cells and 106 CD45.1+ B6 WT T cells. (G) Dot plot show the percentage of donor allogeneic CD47 KO T cells identified as CD45.1H2-Kb+TCR-+ cells and 
donor WT T cells identified as CD45.1+H2-Kb+TCR-+ cells in allogeneic recipient mice on day 6 after allo-HCT. (H–J) The percentages of CD47 KO T cells (red) and 
WT T cells (blue) among donor allogeneic T cells in recipient mice sacrificed at 2 h (H, n = 2/group), 18 h (I, n = 4/group), or 6 d (J, n = 5/group) after allo-HCT are 
shown as mean ± SEM. (K) Absolute number of donor T cells in allogeneic recipients analyzed 6 d after transfer are shown as mean ± SEM. *, P < 0.05.  
The results are representative of two independent experiments. MZ, marginal zone; RPM, red pulp macrophage. *, P < 0.05.JEM VOL. 208, May 9, 2011 
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Pretransplant CSF-1 treatment expands host macrophages 
and improves GVHD after allo-HCT
Human CSF-1 has been shown to expand macrophages in mice 
(Hume et al., 1988; Cecchini et al., 1994). To examine whether 
pretransplant CSF-1 administration could be used to improve 
GVHD after allo-HCT, recipient C57BL/6 mice were injected 
daily for 5 d with high-dose human CSF-1 before lethal irradia-
tion and allo-HCT. CSF-1 injections significantly increased the 
number of host spleen macrophages that persisted after lethal   
irradiation (Fig. 8 A). Strikingly, CSF-1 injections also reduced 
the expansion of donor alloreactive T cells in the spleen, LN, 
and liver and the differentiation of IFN-–producing effector 
cells (Fig. 8, B–E) but did not alter the induction of donor 
Foxp3+ regulatory T cells (Fig. 8 F). Importantly, pretransplant 
CSF-1  treatment  significantly  improved  the  clinical  GVHD 
score and survival of recipient mice injected with 10 or 20 × 106 
splenocytes (Fig. 8, G–J). Consistently, the loss of CD4+CD8+ 
double-positive T cells in the thymus, a surrogate marker of 
thymic GVHD (Krenger et al., 2000), was significantly im-
proved by CSF-1 administration (Fig. 8 K).
DISCUSSION
Our study identifies the unexpected key role of host macro-
phages in modulating GVHD morbidity and mortality after 
allo-HCT. In this paper, we show that host macrophages 
persist in lymphoid organs for several days after allo-HCT 
and are critical to limit host tissue damage by donor alloreactive 
T cells. We also establish that pretransplant CSF-1 adminis-
tration improves GVHD in transplanted animals through the 
expansion of the host macrophage pool.
These results came as a surprise because the current dogma 
suggests that host APCs, including DCs and macrophages, con-
tribute to the induction of GVHD. This concept is based on 
experiments showing that the pretransplant conditioning regi-
men leads to the release of inflammatory cytokines by host 
macrophages (Hill et al., 1997) and that the concomitant deple-
tion of DC and macrophages improves GVHD (Zhang et al., 
2002b). In this study, we revisited the role of macrophages in 
GVHD by developing means to target host macrophages while 
sparing host DC before allo-HCT. To this end, we targeted 
CSF-1R to reduce macrophages, but not DC numbers, in lym-
phoid organs. CSF-1 is required for macrophage development, 
survival, and proliferation in vivo, and mice that lack CSF-1   
or  the  CSF-1R  also  lack  macrophages  in  lymphoid  tissues   
(Cecchini et al., 1994). We have shown in a series of studies 
(Helft et al., 2010) that although CSF-1R controls the homeo-
stasis of specific DC subsets in nonlymphoid tissues (Bogunovic 
et al., 2009; Ginhoux et al., 2009), it does not control the main-
tenance of lymphoid organ DC, and csf-1r/ mice have intact 
lymphoid organ DC populations (Ginhoux et al., 2006, 2009). 
In this paper, we show that CSF-1R blockade before transplant 
eliminates macrophages, but not DC, in lymphoid organs and, 
unexpectedly, enhanced donor T cell expansion and exacer-
bated GVHD morbidity and mortality after allo-HCT.
Figure 8.  CSF-1 administration reduces 
donor T cell expansion and GVHD severity. 
(A) C57BL/6 mice were injected i.p. with 106 U 
human CSF-1 (black bar, n = 11) or diluent 
(white bar, n = 11) daily for 5 d and trans-
planted with 5 × 106 splenocytes and 5 × 106 
BM cells 1 d after the last injection. Splenic 
macrophages were enumerated 24 h after the 
transplant and shown as mean ± SEM. Data 
from three separate experiments were com-
bined. (B–F) C57BL/6 mice were treated with 
CSF-1 (black bar, n = 12) or diluent (white bar, 
n = 12) and transplanted as in A. Bar graphs 
show the number of donor T cells in the 
spleen (B), mesenteric LN (C), and liver (D) and 
the number of IFN-–producing T cells (E) and 
Foxp3+ T regulatory cells in the mesenteric LN 
(F) on day 6 after transplant. Data are shown 
as mean ± SEM. (G–K) C57BL/6 mice were 
treated with CSF-1 (diamonds, solid lines) or 
diluent (triangles, dashed lines) for 5 d and 
injected with 10 × 106 (G, H, and K, n = 10/
group) or 20 × 106 (I and J, n = 5–6/group) 
splenocytes plus 5 × 106 BM cells isolated 
from BALB/c donors 1 d after the last CSF-1 
injection. As controls, recipient mice were 
reconstituted with syngeneic BM cells and splenocytes (G, filled circles, n = 3). Survival curves (G and I) and clinical GVHD scores (H and J) are shown.  
(K) The numbers of thymic CD4+ CD8+ double-positive cells from diluent-treated (gray bar) and CSF-1–treated (black bar) recipients were enumerated on 
day 22 and shown as mean ± SEM. As control, the data from syngeneic recipients (white bar, n = 3) were shown. Data were pooled from two independent 
experiments. *, P < 0. 05; *, P < 0.0001 versus diluent-treated controls1078 CSF-1 modulates graft-versus-host disease | Hashimoto et al.
donor T cells observed in the two studies. Whereas we found 
that AFS treatment significantly increased the donor T cell 
pool as early as 18 h after transplant and did not affect donor 
T regulatory cell differentiation in vivo, the M279 Ab clone 
failed to modulate the numbers of donor allogeneic T cells 
but affected Th1 differentiation and reduced donor T regula-
tory cell expansion in recipient mice.
Our results also suggest that host macrophages limit the 
donor T cell pool directly through their ability to engulf and 
clear donor T cells. CD47 is an integrin-associated protein 
ubiquitously expressed on all hematopoietic cells (Matozaki 
et al., 2009) and its receptor called SIRP (signal regulatory 
protein ) is highly expressed on macrophages (unpublished 
data) and on a subset of DC (Ginhoux et al., 2009). We found 
that naive T cells express lower CD47 levels compared with 
other cell types. We also found that whereas naive allogeneic 
CD47/ T cells are rapidly eliminated upon injection into 
lethally irradiated recipient animals compared with wild-type 
T cells, the survival of allogeneic CD47/ T cells is dramati-
cally prolonged when recipient mice are depleted of their 
macrophage content before transplant. These results strongly 
support CD47 having a key role in controlling macrophage 
ability to modulate the donor allogeneic T cell pool and are 
consistent with prior studies showing that CD47 expression 
by donor hematopoietic cells determine their ability to sur-
vive in recipient animals (Fraser et al., 1995; Blazar et al., 
2001; Abe et al., 2002; Rozemuller et al., 2004; Ide et al., 
2007; Takenaka et al., 2007).
Further supporting the importance of host macrophages 
in regulating allo-HCT outcome, we found that pretrans-
plant injections of the cytokine CSF-1 increased the host 
macrophage pool, limited the expansion of donor alloreac-
tive T cells, and improved GVHD morbidity and mortality. 
Because the half-life of CSF-1 in the circulation does not ex-
ceed 10 min (Bartocci et al., 1987), these results strongly sug-
gest that CSF-1 pretransplant treatment improved the survival 
of mice after allo-HCT by promoting the survival of host 
macrophages and their ability to modulate donor T cell– 
mediated tissue damage. In contrast to a previous report 
showing that CSF-1 administration after allo-HCT interferes 
with donor cell engraftment in recipient mice injected with   
T cell–depleted allografts (Blazar et al., 1992), pretransplant 
use of CSF-1 did not affect the engraftment of donor hema-
topoietic cells in our study (unpublished data). CSF-1 after 
transplant administration was also found to prevent fungal in-
fection in patients after allo-HCT (Nemunaitis et al., 1993), 
although CSF-1 posttransplant therapy to treat GVHD should 
be used with caution, as CSF-1 should also be able to prolong 
the survival of macrophages that infiltrate GVHD target tis-
sue and promote tissue inflammation and fibrosis (Facon et al., 
1995; Namba et al., 2007; Wynn and Barron, 2010).
In conclusion, our study establishes for the first time the 
differential role of host APC in allo-HCT. In this paper, we 
show that although both host DCs and macrophages survive 
the conditioning regimen, they have opposite contribution 
to GVHD outcome. Host DCs prime donor T cells against 
To further establish the role of macrophages in GVHD, we 
administered low-dose Lip-Clod 10 d before transplant to de-
plete host macrophages, whereas host DC, which has a half-life 
in lymphoid tissues that does not exceed 3 d (Merad and Manz, 
2009), would have completely recovered at the time of trans-
plant. Our results revealed that, in contrast to a previous study 
in which higher Lip-Clod doses administered 7 and 2 d before 
transplant led to the depletion of both DC and macrophages 
and improved GVHD (Zhang et al., 2002b), low-dose Lip-
Clod administered 10 d before transplant depleted host macro-
phages, but not DC, and aggravated GVHD.
Anti–CSF-1R mAb administration also reduced the num-
ber of circulating monocytes and affected the Gr-1low mono-
cyte subset more dramatically, suggesting that CSF-1R controls 
the differentiation of Gr-1high into Gr-1low monocytes in vivo. 
Because monocytes also limit T cell expansion after organ 
transplant (Garcia et al., 2010), they could potentially also 
modulate GVHD outcome in mice treated with anti–CSF-1R 
mAb. The role of circulating monocytes in GVHD, however, 
appears to be unlikely, as circulating monocytes are sensitive to 
radiation and nearly absent from the host at the time of trans-
plant. In addition, mice that received Lip-Clod 10 d before 
allo-HCT and have recovered the number of monocytes to 
normal levels (Tacke et al., 2006) at the time of transplant de-
veloped more severe GVHD compared with control groups 
(unpublished data).
Our  data  also  suggest  that  host  macrophages  improve 
GVHD by limiting the expansion of donor alloreactive T cells. 
The immunomodulatory role of macrophages has already been 
reported in several settings. In tumors, for example, macro-
phages modulate T cell function through several mechanisms 
that include, but are not limited to, the production of iNOS, 
arginase1, and IDO (Pollard, 2004; Allavena et al., 2008). Al-
though these molecules have been shown to modulate GVHD 
after allo-HCT (Drobyski et al., 1994; Krenger et al., 1996; 
Blazar et al., 2003; Banovic et al., 2005; Jasperson et al., 2009), 
blockade of IL-10, IDO, iNOS, or arginase 1 at least individu-
ally failed to interfere with macrophage ability to suppress   
donor T cell expansion in vitro. Blockade of TGF- was able 
to partly restore donor T cell proliferation, suggesting its po-
tential role in regulating recipient macrophage ability to con-
trol donor T cell expansion in vivo.
The aggravating effect of CSF-1R blockade identified in 
this paper is consistent with a recently published study show-
ing that an antibody to CSF-1R (M279 clone), distinct from 
the AFS98 clone used in our study, also aggravated GVHD 
outcome after allo-HCT in mice (MacDonald et al., 2010). 
Although this study did not identify the cellular target that 
control GVHD aggravation upon injection of the M279 Ab 
clone, it is likely that it differs from the cells targeted by the 
AFS98 clone. In contrast to AFS98, injection of the M279 
Ab clone did not deplete spleen red pulp and LN medullary 
macrophages  and  affected  mainly  LN  subcapsular  macro-
phages, perifollicular macrophages in the spleen, and tissue-
resident macrophages. The different target cell populations 
between the clones might explain the differential fate of   JEM VOL. 208, May 9, 2011 
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60 min (liver and lung) and then passed trough a 70-µm cell strainer (BD) to 
obtain  a  homogeneous  cell  suspension.  Epidermal  sheets  were  prepared   
using 2.4 mg/ml Dispase (Invitrogen) and further digested with collagenase 
as previously described (Ginhoux et al., 2007). Liver DC subsets were pre-
pared as previously described (Ginhoux et al., 2009). Isolation of gut DC 
subsets was performed as previously described (Bogunovic et al., 2009). Red 
blood cells were lysed by incubating with RBC Lysis buffer (eBioscience) 
for 2 min. Fluorochrome or biotin-conjugated mAb specific to mouse F4/80 
(BM-8), B220 (RA3-6B2), TCR- (H57-597), CD4 (L3T4), CD8a (53–6.7), 
IA/IE (M5/114.15.2), CD11b (M1/70), CD11c (N418), CD45 (30F11), 
CD45.1  (A20),  CD45.2  (104),  Gr-1  (Rb6-8C5),  anti-Foxp3  (FJK-16s), 
CD47 (clone miap301), and PE- or PE-Cy7–conjugated streptavidin were 
purchased from eBioscience. Biotinylated and Alexa Fluor 647–conjugated 
anti–mouse  F4/80  (CI:A3-1)  and  FITC-conjugated  anti–mouse  CD169 
mAb (3D6.112) were purchased from AbD Serotec. FITC- or PE-conjugated 
anti–H-2Kd (SF1-1.1) was purchased from BD. Blocking of FcR was   
performed by incubating the cells with anti–mouse CD16/32 mAb (clone 
93 or 2.4G2). DAPI (Vector Laboratories)-positive cells were excluded from 
analysis as dead cells. For intracellular IFN- staining, the splenocytes were 
incubated for 4 h with 500 ng/ml ionomycin and 50 ng/ml phorbol ester 
(Sigma-Aldrich), and 2 µg/ml brefeldin A (Sigma-Aldrich) at 37°C before 
permeabilization with a Cytofix/Cytoperm solution (BD). The cells were 
then stained with APC-conjugated anti–IFN- mAb (clone XMG1.2; eBio-
science). Multiparameter analyses were performed on an LSR II (BD) and 
sorting was performed on FACS Aria II cell sorter (BD).
Cytokine bead array (CBA) analysis. Blood was collected from the retro-
orbital sinus on day 6 after transplant, and the concentrations of Th1 cyto-
kines (IFN- and TNF) and Th2 cytokines (IL-4 and IL-13) were measured 
using the CBA kit according to the manufacturer’s protocol.
In  vitro  co-culture  assays.  Splenic  macrophages  were  purified  as   
F4/80highCD11blowMHC-IIlow cells, peritoneal macrophages were purified 
as F4/80high cells, DCs were purified as CD11chighMHC-IIhigh cells, and B 
cells were purified as B220+MHC-II+CD11c cells from the spleen of naive 
or transplanted C57BL/6 or BALB/c. T cells were purified from the LN of 
naive C57BL/6 or BALB/c mice using magnetic negative selection. 5 × 104   
T cells were stimulated with 5 × 103 DCs in the presence or absence of puri-
fied macrophages as indicated in the text. Cells were cultured in 96-well 
plates in complete DME (Invitrogen) supplemented with 10% FCS, 50 U/ml 
penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium   
pyruvate, 0.1 mM nonessential amino acids, 50 µM 2-ME, and 10 mM   
Hepes for 72 h. In some cases, macrophages were separated from the 
DC/T cell co-cultures by membrane with 1 µm pore (Corning). As indicated   
in the text, the following inhibitors were added: iNOS inhibitor, L-NMMA 
(NG-Methyl-l-arginine acetate; EMD) at 500 µM; ARG1 inhibitor, nor-
NOHA (Nw-hydroxy-nor-Arginine; EMD) at 500 µM; iNOS inhibitor, 
1-MT (1-methyl-dl-tryptophan; Sigma-Aldrich) at 20 µM; anti–IL-10 neu-
tralizing Ab (clone: JES5-2A5; eBioscience) at 10 µg/ml; and anti–TGF- 
neutralizing Ab (clone: 1D11; R&D Systems) at 30 µg/ml. In some experi-
ments, T cells were stimulated with 5 µg/ml of plate-bound anti-CD3 
mAb (eBioscience) and 2 µg/ml anti-CD28 mAb (eBioscience). Cultured 
wells were pulsed with [3H]-Thymidine (0.5 µCi/well; GE Healthcare) for 
the final 16 h of culture, and [3H]-Thymidine-uptake was determined, using 
a Wallac 1450 MicroBeta Counter (Perkin Elmer). When indicated, purified 
T cells were labeled with 5 µM CFSE (Invitrogen) or 2 µM PKH26 before 
being incubated with DCs and macrophages for 5 d. CFSE expression levels 
on gated T cells were determined by LSRII.
Microscopy  analysis.  For  immunofluorescent  analysis,  isolated  spleens 
were fixed with 4% PFA and 10% sucrose solution, frozen in O.C.T. com-
pound (Sakura), and cut into 6-μm tissue section slides. Tissue sections were 
incubated with 10% goat serum for 30 min, followed by anti–mouse CD3 
(clone 500A2; BD) mAb and biotinylated anti–mouse F4/80 (CI:A3-1) or 
CD169 (clone MOMA-1; Abcam) mAb. Endogenous biotin was blocked 
host tissue antigens and initiate GVH reactions. In contrast, 
remaining host macrophages reduce the donor T cell pool 
through their ability to engulf alloreactive T cells and to modu-
late their proliferation and, consequently, limit the severity of 
GVHD. Our study also identifies pretransplant CSF-1 ther-
apy as a novel clinical strategy for the modulation of GVHD 
severity in patients undergoing allo-HCT.
MATERIALS AND METHODS
Mice.  Female  C57BL/6  (H-2b,  CD45.2+),  C57BL/6-Ly5a  (C57BL/6-
CD45.1,  H-2b,  CD45.1+),  BALB/c  (H-2d),  C57BL/6J-Tg  (Csf1r-GFP, 
NGFR/FKBP12;  MaFIA;  Burnett  et  al.,  2004),  C57BL/6-csf-1op/op, 
B6.129S4-C3tm1Crr/J  (C3-deficient  mice),  B6.129S7-CD47tmFpl/J  (CD47-
deficient  mice),  B6.129P2-Nos2tm1Lau/J  (iNOS-deficient  mice),  and 
B6.129S7-Ifngtm1Ts/J (IFN-R–deficient mice) were purchased from The 
Jackson Laboratory. B6.129P2-Fcer1gtm1Rav N12 mice (mice deficient in the 
Fc chain subunit of the Fc receptor I (FcgRI), FcgRIII, and FceRI recep-
tors, as described in Takai et al. (1994), were purchased from Taconic. FVB/
NJ-Csf1r/ and littermate FVB/NJ-Csf1r+/ mice were produced as previ-
ously described (Dai et al., 2002). csf1op/op and csf1r/ mice were 3–4 wk old, 
whereas all other mice used were 8–12 wk old. Mice were maintained in 
specific pathogen-free condition and received normal chow and hyperchlo-
rinated drinking water for the first 3 wk after allo-HCT. All animal experi-
ments were performed according to protocols approved by the Institutional 
Committee on Animal Welfare of the Mount Sinai School of Medicine.
allo-HCT. Mice were exposed to TBI split into two doses separated by 4 h 
to minimize gastrointestinal toxicity. C57BL/6 mice received 13 Gy TBI, 
whereas BALB/c mice received 8.5 Gy TBI. 2 h after irradiation, mice were 
injected i.v. with 5 × 106 BM cells in addition to 2.5–20 × 106 splenocytes 
isolated from donor mice as indicated in the text. In some experiments, puri-
fied T cells were injected into lethally irradiated animals with or without   
T cell–depleted BM cells. T cells were purified by negative selection from the 
lymph nodes of donors, using a pan T cell isolation kit and the AutoMACS 
Pro Separator (Miltenyi Biotec) according to the manufacturer’s instructions 
to achieve 99% purity. T cell depletion was done with CD90-microbeads 
(Miltenyi Biotec) and AutoMACS Pro. Some recipient animals were injected 
with anti–CSF-1R mAb (CSF-1R, clone AFS98) at doses of 2 mg/mouse 
on day 5 and 0.5 mg/mouse on days 4 and 3. CSF-1R mAb was puri-
fied from culture supernatant of AFS98 hybridoma (Sudo et al., 1995), grown 
in a CELLine Flask (BD) in serum-free medium (PFHM-II; Invitrogen). 
Clodronate (Roche) was encapsulated in liposomes by N. van Rooijen. 100 µl 
Lip-Clod was administered at day 10 before allo-HCT. In some experi-
ments, 106 U/d of human CSF-1 (Kyowa Hakko Kirin Co., Ltd.) was in-
jected i.p. daily from day 5 to 1 before allo-HCT. Survival after allo-HCT 
was monitored daily and the clinical GVHD scores were assessed weekly   
using a scoring system that sums the changes in five clinical parameters that 
include the weight loss, posture, activity, fur texture, and skin integrity (maxi-
mum index = 10) as previously described (Cooke et al., 1996). To evaluate 
the histological GVHD scores, formalin-preserved livers and small and large 
bowels were embedded in paraffin, cut into 5-µm-thick sections, and stained 
with H&E for histological examination. Slides were examined in a blinded 
fashion by a pathologist (C. Liu). A semiquantitative scoring system was used 
to assess the severity of histological GVHD (Hill et al., 1998).
GW2580. GW2580 (LC Laboratories) was suspended in 0.5% methylcellu-
lose and 0.1% Tween 20 by using multiple strokes with a Teflon-glass ho-
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using Avidin/Biotin blocking kit (Vector Laboratories). The primary mAbs 
were  detected  by  incubating  the  slides  with  Cy3-conjugated  anti-syrian 
hamster IgG and Cy5-conjugated streptavidin (Jackson ImmunoResearch 
Laboratories).  To  determine  whether  macrophages  engulfed  allogeneic   
T cells, splenocytes isolated from recipient mice 18 h after transfer of CFSE-
labeled alloreactive T cells and in vitro–cultured cells (as described in the 
previous section) isolated after 18 h of co-culture were stained with biotinyl-
ated F4/80 antibody, followed by Cy-5–conjugated streptavidin, fixed with 
2% PFA, cytospun onto slides, and analyzed by microscopy. The images 
were captured using a microscope (Axioplan 2IE; Carl Zeiss) equipped with 
a camera (AxioCam MR; Carl Zeiss) and an encoded motorized stage that 
automates image acquisition of large areas. The images were analyzed using 
ImageJ software (National Institutes of Health) and Photoshop CS3 (Adobe) 
and integrated with other figures using Illustrator CS3 (Adobe).
Statistical analysis. Data analysis was performed with FlowJo v8 software 
(Tree Star). Data are presented as mean ± SEM. The statistical significance 
of differences between group means was determined using Mann-Whitney 
U test. Survival curves were plotted by the Kaplan-Meier method. The level 
of significance was set at P < 0.05.
Online supplemental material. Fig. S1 shows that neutrophils, T cells, and 
NK cells are rapidly eliminated after TBI. Fig. S2 shows that lymphoid tissue 
macrophages are strongly reduced in CSF-1– and CSF-1R–deficient mice. 
Fig. S3 shows that anti–CSF-1R mAb treatment does not affect neutrophils 
and lymphoid cell homeostasis. Fig. S4 shows that anti–CSF-1R mAb treat-
ment depletes macrophages independently of ADCC or complement-de-
pendent cytotoxicity. Fig. S5 shows that anti–CSF-1R mAb injection acts 
on host cells to limit donor T cell pools without affecting donor foxp3+  
T cells. Fig. S6 shows that nonlymphoid tissue-resident DCs are not affected 
in mice that received Lip-Clod 10 d before analysis. Fig. S7 shows that host 
macrophages suppress T cell proliferation in vitro. Fig. S8 shows that CD47 
is expressed at lower levels on naive T lymphocytes compared with B cells 
and is up-regulated on activated T cells. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20101709/DC1.
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